Filing Details

Accession Number:
0001632388-15-000007
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-02-10 15:11:37
Reporting Period:
2015-02-10
Filing Date:
2015-02-10
Accepted Time:
2015-02-10 15:11:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1618561 Nexvet Biopharma Plc NVET Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1632741 Ii Fund Healthcare Pacific Asia Atf Ltd Management Funds One Level 11, 20 Hunter Street
Sydney C3 2000
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2015-02-10 530,972 $0.00 530,972 No 4 C Direct
Ordinary Shares Acquisiton 2015-02-10 242,400 $0.00 773,372 No 4 C Direct
Ordinary Shares Acquisiton 2015-02-10 100,000 $10.00 873,372 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series A Investment Preference Shares Disposition 2015-02-10 530,972 $0.00 530,972 $0.00
Ordinary Shares Series B Preference Shares Disposition 2015-02-10 242,400 $0.00 242,400 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Reflects automatic conversion of Series A Investment Preference Shares into ordinary shares on a one-for-one basis upon the completion of the initial public offering of Issuer's ordinary shares.
  2. Justin Epstein, as the authorized director of One Funds Management Limited, the trustee for Asia Pacific Healthcare Fund II, has voting and dispositive power with respect to these reported securities, but disclaims beneficial ownership thereof except to the extent of his pecuniary interest therein.
  3. Reflects automatic conversion of Series B Preference Shares into ordinary shares on a one-for-one basis upon the completion of the initial public offering of Issuer's ordinary shares.